Printer Friendly

Hitachi Co-develops Compact Automatic Virus Detection System with Takara Bio.

Tokyo, Japan, Oct 15, 2005 - (JCNN) - Hitachi, Ltd. has developed compact automatic virus detection system jointly with Takara Bio. The system comprises Hitachi's proprietary virus collection system and virus genes analyzer, developed based on Takara Bio's ICAN (Isothermal and Chimeric Primer-Initiated Amplification of Nucleic Acids) method.

Equipped with two MEMS (Micro Electro Mechanical Systems) chips, the system saves significantly virus collection and analysis processes, which used to require a week or so, so making the total system fit within 50(W)x45(L) cm.

Setting the MEMS chips, which concentrate and collect virus through the collector, inside the analyzer allows for detection of the virus genes in 40 to 120 minutes. After the process, only the chips need disposing of, which helps reduce examiners' chance to be virus-affected.

Hitachi expects the portable system to meet on-spot virus detection needs at care facilities for the elderly, food processing factories, airports and seaports. It aims for sales of total 10 billion yen for the next three years.

Source: JCN http://www.japancorp.net

Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Geographic Code:9JAPA
Date:Oct 15, 2005
Words:181
Previous Article:Mochida Pharmaceutical Adopts British Inpharmatica's In-silico ADME Suite, Admensa Interactive.
Next Article:NTT Data Develops Patent Document Analysis System Based on Natural Language Processing Technology.
Topics:


Related Articles
NANOSPHERE/TAKARO BIO FORM DEVELOP/DISTRIBUTE ALLIANCE.
Takara Bio Introduces New Protein Expression System.
Takara Bio, MolMed Announce That Phase I/II Clinical Trial of HSV-TK Gene Therapy Delivers Positive Results.
Takara Bio Chinese Subsidiary to Expand Lines of Business, Files Chinese Clinical Trial Application.
Takara Bio Licenses FLT3 Gene Mutation Detection Method to InVivoScribe Technologies.
HitachiSoft to Launch New Johmon Finger Vein Authentication System; Collaboration with Hitachi Ltd. Produces More Compact, Lower-priced Finger Vein...
Takara Bio Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis.
Rapid genome sequencing of RNA viruses.
HitachiSoft Launches SaaSWare SynchroMax Services Linking Salesforce and Groupmax Groupware, Synchronizing Schedules.
Takara Bio Grants Transgenomic License for LA-PCR Technology.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters